window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Ingredients

  • Ingredients,Manufacturing,Packaging,Pharmaceuticals and therapeutics

    BIOGRUND and Seprify launch plant-based tablet coating to replace titanium dioxide

    BIOGRUND and Seprify have introduced a plant-based tablet coating system [...]

    April 7, 2026
  • CDMOs & Manufacturing,Drug Delivery & Formulation,Facilities and infrastructure,Ingredients,Manufacturing,Technology and platforms

    DFE Pharma launches continuous manufacturing platform with Gericke to support formulation development

    DFE Pharma has launched a new continuous manufacturing platform in [...]

    February 18, 2026
  • Ingredients,Manufacturing,Pharmaceuticals and therapeutics,Sustainability

    DFE Pharma launches EcoLact 2030 to cut CO₂ emissions across lactose excipients

    DFE Pharma has launched EcoLact 2030, a sustainability programme covering [...]

    February 5, 2026
  • Ingredients,Manufacturing,Supply Chain & Logistics

    Video: ADM outlines glycerin excipient focus at CPHI Frankfurt

    December 19, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top